Patricia L. Kandalaft

Author

City Of Hope National Medical Center

Also Known As

P Kandalaft, P L Kandalaft, P. L. Kandalaft, Patricia Kandalaft, Patricia L Kandalaft, Patricia L. Kandalaft

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

City Of Hope National Medical Center University of Washington Medical Center Golder Associates (Canada)

About

Patricia L. Kandalaft is an author at City Of Hope National Medical Center specializing in pathology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	725
2	Immunology	3	3	456
3	Cell Biology	2	2	351
4	Health Sciences	1	1	44
5	Endocrinology	1	1	44

Patricia L. Kandalaft

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
The Human Hematopoietic Progenitor Cell Antigen (CD 3 4) in Vascular Neoplasia S. Thomas Traweek, Patricia L. Kandalaft, Parula Mehta, American Journal of Clinical Pathology ImmunologyBlood CellPathologyCd 3Endothelial Cell Derivation	1991	302
Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? Kimberly H. Allison, Patricia L. Kandalaft, Colleen M. Sitlani, Breast Cancer Research and Treatment Routine Pathologic ParametersDisease ProgressionMedicineDifferential DiagnosisDiagnostic Criterion	2011	126
Determining True <i>HER2</i> Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-<i>HER2</i> Targeted Therapy Chun Hing Tse, Harry C. Hwang, Lynn C. Goldstein, Journal of Clinical Oncology	2011	119
Vimentin-Negative Epithelioid Sarcoma Daniel A. Arber, Patricia L. Kandalaft, Parula Mehta, The American Journal of Surgical Pathology Tumoral PathologyFocal VimentinMedicineSurgical PathologyHistopathology	1993	105
Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site Patricia L. Kandalaft, Allen M. Gown Archives of Pathology & Laboratory Medicine	2015	105
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system Allen M. Gown, Lynn C. Goldstein, Todd Barry, Modern Pathology Her2 StatusImmunocytochemical TechniqueOncologyBreast OncologyCancer Detection	2008	99
Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer Patricia L. Kandalaft, Karen Chang, Chul Ahn, Cancer	1993	55
Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections Patricia L. Kandalaft, Rochelle A. Simon, Christina Isacson, Applied immunohistochemistry & molecular morphology Breast OncologyMammaglobin AImmunologyPathologyTumor Biology	2015	49
Improvement of the Quantification of Estrogen and Progesterone Receptors in Paraffin-Embedded Tumors by Image Analysis José Miguel Esteban López-Jamar, Patricia L. Kandalaft, Parula Mehta, American Journal of Clinical Pathology Breast OncologyEstrogen ReceptorGynecologyPathologyComputerized Image Analysis	1993	44
The Lung-Restricted Marker Napsin A Is Highly Expressed in Clear Cell Carcinomas of the Ovary Patricia L. Kandalaft, Allen M. Gown, Christina Isacson American Journal of Clinical Pathology	2014	43

Page 1